Tofogliflozin Reduces 24-h Ambulatory Blood Pressure in inpatients with Type 2 Diabetes and Hypertension

Tofogliflozin Reduces 24-h Ambulatory Blood Pressure in inpatients with Type 2 Diabetes and Hypertension - The Influence of Tofogliflozin on 24-h Ambulatory Blood Pressure

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022580

Enrollment

Registered

2016-06-15

Start date

2016-06-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes with hypertension

Interventions

ABPM was performed twice time at pretreatmentand posttreatment for 1week of tofogliflozin.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)patient with type 2 diabetesand hypertension doing a hospitalizing for diabetes treatment 2)Patients treated with Angiotensin Receptor Blocker(ARB) and/or Angiotensin Converting Enzyme Inhibitors(ACE-I) for hypertension 3) SBP>140mmHg and/or DBP>90mmHg

Exclusion criteria

Exclusion criteria: 1) Type 1 diabetes 2) Severe diabetic complications such as ketoacidosis 3) Severe renal dysfunction(estimated glomerular filtration rate [eGFR] < 30 mL/min/) 4) Pregnant or nursing women and those who might be pregnant 5) Chronic heart failure, 6) Haemodialysis, 7) A history of stroke and cardiovascular events, 8) Any patient whom the investigator judged to be inappropriate for this study.

Design outcomes

Primary

Measure	Time frame
24h-blood pressure(systolic and diastolic) before and after the administration of 20mg tofogliflozin.	—

Secondary

Measure	Time frame
Holter electrocardiograph,power spectrum analysis,NT-proBNP and D-ROMs before and after the administration of tofogliflozin.	—

Countries

Japan

Contacts

Public ContactKunihiro Suzuki

Dokkyo Medical University Endocrinology and Metabolism

kuni-s@dokkyomed.ac.jp0282-87-2150

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026